Skip to main content
TipRanks
Go Ultimate75% OFF

Kringle Pharma, Inc. (4884) Stock Price & Analysis

0 Followers

4884 Stock Chart & Stats

¥557.00¥38.00(7.32%)
At close: 3:30 PM GMT+9
¥400¥500¥600¥700Aug 17Aug 31Sep 14Sep 28Oct 13Oct 26Nov 9
Day’s Range
JPY 509.00 - JPY 584.00
52-Week Range
JPY 287.00 - JPY 741.00
Previous Close
JPY 519.00
Volume
N/A
Average Volume (3M)
431.36K
Market Cap
JPY 4.79B
Enterprise Value
JPY 1.08B
Total Cash (Recent Filing)
JPY 1.70B
Total Debt (Recent Filing)
JPY 0
Price to Earnings (P/E)
―
Beta
0.59
Next Earnings
Feb 05, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

High Gross Margin

The approximately 84% gross margin indicates strong economics on revenue already generated and leaves meaningful room to cover operating costs if scale improves. While insufficient to offset current expenses today, this margin profile could support future profitability if revenue becomes more consistent.

Revenue Rebound

The latest revenue rebound demonstrates that Kringle Pharma can generate materially higher sales than its depressed 2025 base. Sustaining or building on this recovery would improve operating leverage, strengthen commercial traction, and provide a larger base from which to absorb fixed research and corporate costs.

Zero Debt

A debt-free balance sheet reduces refinancing exposure and eliminates interest-rate pressure that could otherwise compound the company’s operating losses. This gives management greater financial flexibility to allocate available capital toward development and operations without servicing a lender-funded capital structure.

Bears Say

Persistent Net Losses

Persistent, substantial net losses show that the current business has not yet converted its high gross margin into a sustainable earnings model. Continued losses can require repeated external funding, limit strategic flexibility, and make future profitability dependent on significant cost improvement or further revenue expansion.

Operating Cash Burn

Deeply negative operating cash flow indicates that ongoing activities consume cash rather than fund themselves. This weakens financial resilience over the next several quarters and raises the importance of maintaining funding access while the company works to develop products and reach a self-sustaining operating model.

Eroding Equity Base

The sustained decline in equity reflects the cumulative effect of ongoing losses and reduces the capital cushion available to support future operations. Even without debt, continued equity erosion can increase dependence on new capital and weaken the company’s ability to absorb delays in revenue or product development.

Kringle Pharma, Inc. News

4884 FAQ

What was Kringle Pharma, Inc.’s price range in the past 12 months?
Kringle Pharma, Inc. lowest stock price was ¥287.00 and its highest was ¥741.00 in the past 12 months.
What is Kringle Pharma, Inc.’s market cap?
Kringle Pharma, Inc.’s market cap is ¥4.79B.
When is Kringle Pharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kringle Pharma, Inc.’s earnings last quarter?
Kringle Pharma, Inc. released its earnings results on Nov 11, 2026. The company reported -¥20.872 earnings per share for the quarter.
Is Kringle Pharma, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Kringle Pharma, Inc. pay dividends?
Kringle Pharma, Inc. does not currently pay dividends.
What is Kringle Pharma, Inc.’s EPS estimate?
Kringle Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kringle Pharma, Inc. have?
Kringle Pharma, Inc. has 8,593,200 shares outstanding.
What happened to Kringle Pharma, Inc.’s price movement after its last earnings report?
Kringle Pharma, Inc. reported an EPS of -¥20.872 in its last earnings report. Following the earnings report the stock price went up 0.385%.
Which hedge fund is a major shareholder of Kringle Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4884
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology